Edward Van Wezel

Edward van Wezel is founder and Managing Partner at BioGeneration Ventures (BGV), Naarden, The Netherlands. He has extensive international expertise in pharma and biotech companies and currently serves on the supervisory boards of Cristal Therapeutics, Synaffix, Staten Biotechnology, Escalier BioSciences, Scenic Biotechnology, VarmX and Confo Therapeutics.

Edward was instrumental in several of BGV’s recent exits: in 2018 portfolio company Staten Biotechnology secured an exclusive option agreement with Novo Nordisk whereby Staten Biotechnology is entitled to receive up to EUR 430 million. Edward was also founding investor and board member of Acerta Pharma which was acquired in 2016 by AstraZeneca for USD 7 billion including an upfront payment of USD 4 billion.

Edward started his industrial career as a process engineer for Chiron Inc. He also worked as project manager at Johnson & Johnson, where he was responsible for product development projects in the oncology franchise and was involved in corporate licensing activities. Since 2000 he gained experience as Chief Executive Officer of several early startup companies in the Netherlands.

Edward holds a Master degree in Chemistry from the University of Utrecht and a Master in Biochemical Engineering from the Delft University of Technology.